What is the 13F Pro Quality Score for IRD?

13F Pro ranks Opus Genetics, Inc. (IRD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IRD's current score at https://13fpro.ai/company/IRD (free sign-up required for the full ranking).

Where does 13F Pro source IRD data?

All Opus Genetics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Opus Genetics, Inc. files with the SEC under CIK 1228627. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IRD in?

Opus Genetics, Inc. (IRD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IRD research updated on 13F Pro?

IRD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Opus Genetics, Inc.(IRD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1228627 IRD stock profile & AI dashboard →

13F Pro Quality Score

13.4/100

Rank #2,875 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why IRD Scores 13/100

exact factor attribution · 2026-09-11

IRD's composite is driven by institutional flow, held back by revenue growth and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Institutional flow

+1.4 pts

78th pct

Earnings quality

-0.1 pts

49th pct

Shareholder dilution

-1.9 pts

12th pct

Earnings growth

-2.2 pts

5th pct

Capital efficiency

-4.8 pts

2th pct

Scale

-6.4 pts

8th pct

Free cash flow

-6.5 pts

7th pct

Profitability

-6.7 pts

5th pct

Revenue growth

-9.3 pts

4th pct

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

IRD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Opus Genetics, Inc. (IRD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IRD at 13.4/100 on a 32-signal composite quality model, placing it at rank #2,875 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Opus Genetics, Inc. reports quarterly revenue of $755.0K, net income of $-8.1M. Top institutional holders of IRD by reported 13-F value include Caligan Partners, ADAGE CAPITAL PARTNERS GP, L.L.C., BIOS Capital Management, based on the most recent SEC filings. IRD trades on the Nasdaq exchange and files with the SEC under CIK 1228627. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IRD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Opus Genetics, Inc. directly from SEC EDGAR. Opus Genetics, Inc.'s 13F Pro composite quality score has ranged between 13 and 31 since 2024, currently 13.4 — a declining long-term trajectory across 11 quarterly and live scoring snapshots.

Revenue

Q2 2026

$755.0K

Net Income

Q2 2026

$-8.1M

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+29.1% YoY

$14.2MFY 2025

FY22 $39.9MFY23 $19.0MFY24 $11.0MFY25 $14.2M

Net Income

+13.8% YoY

$-49.6MFY 2025

FY22 $17.9MFY23 $-10.0MFY24 $-57.5MFY25 $-49.6M

Operating Income

+37.8% YoY

$-38.6MFY 2025

FY22 $18.2MFY23 $-10.6MFY24 $-62.1MFY25 $-38.6M

EPS (Diluted)

+62.8% YoY

$-0.80FY 2025

FY22 $0.87FY23 $-0.46FY24 $-2.15FY25 $-0.80

Total Assets

+36.3% YoY

$50.2MFY 2025

FY22 $49.0MFY23 $53.9MFY24 $36.9MFY25 $50.2M

Total Debt

$1.1MFY 2025

FY22 $0.00FY23 —FY24 $0.00FY25 $1.1M

Op. Cash Flow

-37.8% YoY

$-35.3MFY 2025

FY22 $14.3MFY23 $-1.1MFY24 $-25.6MFY25 $-35.3M

Free Cash Flow

—FY 2025

FY22 —FY23 —FY24 —FY25 —

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$14.2M +29.1%	$11.0M -42.3%	$19.0M -52.2%	$39.9M +6665.7%	$589.0K	$0.00
Net Income	$-49.6M +13.8%	$-57.5M -476.1%	$-10.0M -155.8%	$17.9M +131.6%	$-56.7M -130.3%	$-24.6M
Operating Income	$-38.6M +37.8%	$-62.1M -487.7%	$-10.6M -158.0%	$18.2M +180.3%	$-22.7M -13.7%	$-20.0M
EPS (Diluted)	$-0.80 +62.8%	$-2.15 -367.4%	$-0.46 -152.9%	$0.87 +122.8%	$-3.82 +23.6%	$-5.00
Total Assets	$50.2M +36.3%	$36.9M -31.7%	$53.9M +10.1%	$49.0M +87.9%	$26.1M +47.5%	$17.7M
Total Debt	$1.1M	$0.00	—	$0.00 -100.0%	$538.0K	$0.00
Operating Cash Flow	$-35.3M -37.8%	$-25.6M -2200.0%	$-1.1M -107.8%	$14.3M +173.9%	$-19.4M -185.0%	$-6.8M
Free Cash Flow	—	—	—	—	—	$-6.8M

Get alerted when IRD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Opus Genetics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IRD

Caligan Partners LP
$25.0M6,077,084 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$24.8M6,029,775 sh
BIOS Capital Management, LP
$15.1M3,683,429 sh
BlackRock, Inc.
$12.8M3,116,487 sh
BALYASNY ASSET MANAGEMENT L.P.
$12.7M3,087,866 sh
Nantahala Capital Management, LLC
$12.6M3,061,359 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.2M2,958,683 sh
Boxer Capital Management, LLC
$11.6M2,815,000 sh
Trails Edge Capital Partners, LP
$11.3M2,743,658 sh
MILLENNIUM MANAGEMENT LLC
$9.5M2,302,101 sh

Fund	Value	Shares
Caligan Partners LP	$25.0M	6,077,084
ADAGE CAPITAL PARTNERS GP, L.L.C.	$24.8M	6,029,775
BIOS Capital Management, LP	$15.1M	3,683,429
BlackRock, Inc.	$12.8M	3,116,487
BALYASNY ASSET MANAGEMENT L.P.	$12.7M	3,087,866
Nantahala Capital Management, LLC	$12.6M	3,061,359
VANGUARD CAPITAL MANAGEMENT LLC	$12.2M	2,958,683
Boxer Capital Management, LLC	$11.6M	2,815,000
Trails Edge Capital Partners, LP	$11.3M	2,743,658
MILLENNIUM MANAGEMENT LLC	$9.5M	2,302,101

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IRD on your watchlist

Track score changes the day Opus Genetics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IRD a good stock to buy?

13F Pro's AI-powered analysis of Opus Genetics, Inc. (IRD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IRD are available on the IRD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. IRD is classified as a small company.

Which hedge funds own IRD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IRD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Opus Genetics, Inc.'s investment landscape.